NO941629L - Peptider som inhiberer 1L-1 - Google Patents

Peptider som inhiberer 1L-1

Info

Publication number
NO941629L
NO941629L NO941629A NO941629A NO941629L NO 941629 L NO941629 L NO 941629L NO 941629 A NO941629 A NO 941629A NO 941629 A NO941629 A NO 941629A NO 941629 L NO941629 L NO 941629L
Authority
NO
Norway
Prior art keywords
substituted
ring
amino acid
peptides
inhibit
Prior art date
Application number
NO941629A
Other languages
English (en)
Other versions
NO941629D0 (no
Inventor
Richard Heng
Trevor Glyn Payne
Laszlo Revesz
Beat Weidmann
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of NO941629D0 publication Critical patent/NO941629D0/no
Publication of NO941629L publication Critical patent/NO941629L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Di-, tri og tetrapeptider hvor den siste a-aminosyren er basert på asparaginsyre og bundet til en rest A5 som er H, CF3, -Z1-Z2-Y2 hvor hver av Z^ og Z2 uavhenging er en direkte binding eller en d-aminosyrerest og Y2 er NH2, C^alkylamino, di-CCi^alkyDamino eller et heterosyklisk radikal bundet ved et nitrogen til Z2, -CHj-Xj-Yj hvor Xt er O eller S og Y3 er heteroaryl, -CH2-Y3, substituert fenyl, ringsubstituert fen- oksymetylen eller fenyltiometylen, ringsubstituert pyridyl- oksymetylen, eller et radikal -CHj-Xj-CO-Y, hvor Xj er O eller S og Y4 er trialkylmetyl eller substistuert fenyl eller pyri- dyl, i fri form eller i saltform, og som har farmakologisk aktivitet, f.eks. inhibering av IL-lp-frigivelse.
NO941629A 1991-11-04 1994-05-03 Peptider som inhiberer 1L-1 NO941629L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919123326A GB9123326D0 (en) 1991-11-04 1991-11-04 Improvements in or relating to organic compounds
PCT/EP1992/002472 WO1993009135A1 (en) 1991-11-04 1992-10-29 Peptides inhibiting il-1 beta release

Publications (2)

Publication Number Publication Date
NO941629D0 NO941629D0 (no) 1994-05-03
NO941629L true NO941629L (no) 1994-07-04

Family

ID=10703998

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941629A NO941629L (no) 1991-11-04 1994-05-03 Peptider som inhiberer 1L-1

Country Status (16)

Country Link
EP (1) EP0611375A1 (no)
JP (1) JPH07500828A (no)
AU (1) AU2885292A (no)
CA (1) CA2116653A1 (no)
CZ (1) CZ106794A3 (no)
FI (1) FI942061A7 (no)
GB (1) GB9123326D0 (no)
HU (1) HUT68200A (no)
IL (1) IL103612A0 (no)
MX (1) MX9206306A (no)
NO (1) NO941629L (no)
NZ (1) NZ244985A (no)
PT (1) PT101027A (no)
SK (1) SK51194A3 (no)
WO (1) WO1993009135A1 (no)
ZA (1) ZA928511B (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6008217A (en) * 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
DE69226820T2 (de) * 1991-06-21 1999-05-12 Merck & Co., Inc., Rahway, N.J. Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
CA2129976C (en) * 1992-02-21 2002-09-17 Kevin T. Chapman Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme
EP0618223A3 (en) * 1993-03-08 1996-06-12 Sandoz Ltd Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents.
US5985838A (en) 1993-04-29 1999-11-16 Vertex Pharmaceuticals, Inc. Peptide analogs as irreversible interleukin-1β protease inhibitors
CA2122227A1 (en) * 1993-04-29 1994-10-30 Roland E. Dolle Peptide analogs as irreversible interleukin-1.beta. protease inhibitors
US5462939A (en) * 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
JPH0789951A (ja) * 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
ATE170868T1 (de) * 1993-06-04 1998-09-15 Vertex Pharma Peptid-phosphinyloxymethyl-ketonen als inhibitoren von interleukin-1 beta- konvertierenden enzymen
US5843905A (en) * 1993-06-04 1998-12-01 Vertex Pharmaceuticals, Incorporated Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors
WO1995005192A1 (en) * 1993-08-13 1995-02-23 Merck & Co., Inc. SUBSTITUTED KETONE DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
US5714484A (en) * 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
US5486623A (en) * 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5565430A (en) * 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
GB2292149A (en) * 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
CA2215211A1 (en) * 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US5798442A (en) * 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
EP0761680A3 (en) * 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazole compounds having Interleukin-1beta converting enzyme inhibitory activity
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
WO1997024339A1 (en) 1995-12-27 1997-07-10 Ono Pharmaceutical Co., Ltd. Tetrazole derivatives and drugs containing the same as the active ingredient
US5869519A (en) * 1996-12-16 1999-02-09 Idun Pharmaceuticals, Inc. C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5968927A (en) 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
US6184244B1 (en) * 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
AU6339198A (en) * 1997-02-26 1998-09-18 Ciblex Corporation Inhibitors of leaderless protein export
US6306613B1 (en) 1997-02-26 2001-10-23 Ciblex Corporation Modulators of leaderless protein export and methods for identifying and using the same
JP4499917B2 (ja) 1998-03-09 2010-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド インターロイキン−１β変換酵素のインヒビターとしての１，２−ジアゼパン誘導体
PL204619B1 (pl) 1998-03-19 2010-01-29 Vertex Pharma Pochodna peptydowa, kompozycja farmaceutyczna zawierająca taką pochodną i zastosowanie pochodnej peptydowej
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
US7157430B2 (en) 1998-10-22 2007-01-02 Idun Pharmaceuticals, Inc. (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases
CA2369619A1 (en) * 1999-04-09 2000-10-19 Cytovia, Inc. Caspase inhibitors and the use thereof
US6525024B1 (en) 2000-04-17 2003-02-25 Idun Pharmaceuticals, Inc. Inhibitors of the ICE/ced-3 family of cysteine proteases
EP1282435A2 (en) 2000-05-12 2003-02-12 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
JP2004509120A (ja) * 2000-09-13 2004-03-25 バーテックス　ファーマシューティカルズ　インコーポレイテッド カスパーゼ阻害剤およびそれらの用途
EP1483241A4 (en) 2002-03-08 2006-12-13 Bristol Myers Squibb Co CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
AU2005223767B2 (en) 2004-03-12 2011-12-01 Vertex Pharmaceuticals Incorporated Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
CN1980658A (zh) 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 治疗自身炎性疾病的ice抑制剂
CN101979403A (zh) * 2010-09-13 2011-02-23 沈陵陵 新型半胱氨酸天冬氨酸广谱蛋白酶抑制剂及其制备方法和用途
JP6006908B2 (ja) 2010-11-05 2016-10-12 ブランダイス ユニバーシティＢｒａｎｄｅｉｓ Ｕｎｉｖｅｒｓｉｔｙ Ｉｃｅ阻害化合物およびその使用
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
EP3374361A1 (en) 2015-11-13 2018-09-19 Novartis AG Novel pyrazolo pyrimidine derivatives
WO2026082873A1 (en) 2024-10-17 2026-04-23 Institut National de la Santé et de la Recherche Médicale Use of caspase-1 inhibitors for treating ineffective erythropoiesis in patients suffering from sickle cell disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015577A1 (en) * 1990-04-04 1991-10-17 Black, Roy, A. INTERLEUKIN 1'beta' PROTEASE

Also Published As

Publication number Publication date
EP0611375A1 (en) 1994-08-24
GB9123326D0 (en) 1991-12-18
SK51194A3 (en) 1995-02-08
ZA928511B (en) 1994-05-04
CZ106794A3 (en) 1994-12-15
FI942061L (fi) 1994-05-04
FI942061A0 (fi) 1994-05-04
FI942061A7 (fi) 1994-05-04
PT101027A (pt) 1994-02-28
HU9401303D0 (en) 1994-08-29
AU2885292A (en) 1993-06-07
JPH07500828A (ja) 1995-01-26
NO941629D0 (no) 1994-05-03
MX9206306A (es) 1993-05-01
CA2116653A1 (en) 1993-05-13
HUT68200A (en) 1995-05-29
NZ244985A (en) 1995-06-27
IL103612A0 (en) 1993-04-04
WO1993009135A1 (en) 1993-05-13

Similar Documents

Publication Publication Date Title
DK1531791T3 (da) Forebyggelse og begrænsning af iskæmi
DK162246C (da) Anvendelse af n-(4-phenoxy-2,6-diisopropylphenyl) -n'-tert-butyl-thiourinstof til bekaempelse af hvide fluer
KR960703110A (ko) 길항 펩티드의 GnRH 제조를 위해 유용한 구아니디노 또는 변형된 구아니디노기를 함유하는 페닐알라닌 유도체 또는 동족체의 제조 방법(PROCESS FOR THE PREPA-RATION OF PHENYLALANINE DERIVATIVES OR HOMOLOGUES CONTAIN-ING A GUANIDINO OR MODIFIED GUANIDINO GROUP USEFUL FOR THE PREPARATION GnRH OF ANTAGONISTIC PEPTIDES)
NO974147L (no) Heterocykelkarbonylaminosyre hydroksyetylaminosulfonamid retroviral protease
NO942553L (no) Ny humanproteaseinhibitor av Kunitz-type og varianter derav
DE69012901D1 (de) Hämoregulierende Peptide.
DK482185A (da) Peptider, deres fremstilling og anvendelse som laegemidler
BR9809859A (pt) Guanidina e/ou homólogo de arginina protegidas, composto, processos para a guanidinilaçõ, para preparar homólogos da arginina, para guandinilar aminas e para a sìntese de fase sólida de um peptìdeo compreendendo um ou mais homólogos da argina, e, composto guanidinilados
ES2051647A1 (es) Procedimiento para la preparacion de calcitonina de salmon.
ATE201693T1 (de) Hämoregulierende peptide
DK1359934T3 (da) Tripeptider og tripeptidderivater til behandling af neurodegenerative sygdomme
DK0579785T3 (da) Substituerede benzhydrylaminer som tlslutningsmolekyler til fastfasepeptidsyntese
DK0971886T3 (da) Fremgangsmåde til fremstilling af N-alkyl-N'-nitroguanidiner
ATE92078T1 (de) Pharmakologisch aktive peptide.
DE69433745D1 (de) Modifizierte, verkürzte regulatoren des komplementsystems
ATE285244T1 (de) Tripeptide und deren derivate zur behandlung von postläsionalen krankheiten des nervensystems
ATE178909T1 (de) Inhibitor peptid spezifisch für cathepsin-l
ATE46173T1 (de) Pharmakologisch aktive peptide.
ES2119746T3 (es) Nuevo peptido fisiologicamente activo y agente regulador del metabolismo del calcio que comprende dicho peptido como ingrediente activo.
ES418929A1 (es) Procedimiento para la preparacion de polipeptidos.
DK1390055T3 (da) Tripeptidderivater til behandling af postlæsionale lidelser i nervesystemet
DK0570244T3 (da) Fremgangsmåde til fremstilling af peptider, der har et C-terminalt prolinamid
ES2104416T3 (es) Glicosilamidas de 2-aminoacilamino-2-desoxi-azucares.
DK0717731T3 (da) Antivirale difluorstatonanaloge
DK0655063T3 (da) Ethynyl-alanin-aminodiolforbindelser med piperazinyl-endegruppe eller piperazinylamino-endegruppe til behandling af hyperte